The main objective is to study the impact of cross-reactivity by other flaviviridae (Yellow Fever virus, Tick Born Encephalitis virus, West Nile virus, Japanese Encephalitis virus and Hepatitis C virus) on Dengue IgG serology using enzyme-linked…
ID
Source
Brief title
Condition
- Viral infectious disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main parameter is specificity and positive predictive value of the Dengue
IgG ELISA.
Secondary outcome
nvt
Background summary
Dengue Fever is caused by the DENV virus which is transmitted by the Aedes
Aegypti or Aedes Albopicto. As the habitat of this *tiger mosquito* is
expanding, the risk of dengue becoming endemic is increasing in more temperate
regions like the Netherlands. Primary infections are mostly asyptomatic,
others experience flu-like symptoms and 2-3% of infections evolves to Dengue
Hemorrhagic Fever(DHF) of Dengue Shock Syndrome(DSS). Severe diseases that are
accompanied with extreme fever, hepatomegaly, plasma leakage and cardiovascular
manifestations. In secondary infections the disease evolves into DHF or DSS
more quickly. DENV infections are diagnosed using IgM and IgG serology, which
is prone to false-positives due to other flaviviridae immunity. In order to
improve dengue diagnostics a validation of current diagnostic tools and the
identification of the precise impact of cross-reactivity is key.
Study objective
The main objective is to study the impact of cross-reactivity by other
flaviviridae (Yellow Fever virus, Tick Born Encephalitis virus, West Nile
virus, Japanese Encephalitis virus and Hepatitis C virus) on Dengue IgG
serology using enzyme-linked immune-assays(ELISA) and indirect
immunofluorescense tests (IFT).
Study design
Diagnostic validation case-control study as an internship project for a medical
student in the fourth year of medical school at the UMC St. Radboud Nijmegen.
Study burden and risks
A bloodsample will be obtained from the patient at one single occasion. A
questionnaire concerning the vaccination history and travel history will be
filled in.
The risks for the patient are the potential side-effects of venapunction, e.g.
soreness and small haemorrhage at the puncture site.
Geert Grooteplein 10
6525 GA
NL
Geert Grooteplein 10
6525 GA
NL
Listed location countries
Age
Inclusion criteria
The research population is defined as healthy volunteers (>18-years old) who received a Yellow Fever vaccination or a Tick Born Encephalitis vaccination.
Exclusion criteria
Immuno-compromised patients or pregnancy.
Patients with known coagulopathias.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL40348.091.12 |